Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

Tytuł:
Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.
Autorzy:
Guinan EM; School of Medicine, Trinity College Dublin, Dublin, Ireland. .
Doyle SL; School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland.
Bennett AE; Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.
O'Neill L; Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.
Gannon J; Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.
Elliott JA; Department of Surgery, St. James' Hospital, Dublin, Ireland.
O'Sullivan J; Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, Dublin, Ireland.
Reynolds JV; Department of Surgery, St. James' Hospital, Dublin, Ireland.; Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, Dublin, Ireland.
Hussey J; Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.
Źródło:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2018 May; Vol. 26 (5), pp. 1569-1576. Date of Electronic Publication: 2017 Dec 02.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Berlin : Springer International, c1993-
MeSH Terms:
Physical Functional Performance*
Esophageal Neoplasms/*complications
Muscle Strength/*physiology
Neoadjuvant Therapy/*adverse effects
Sarcopenia/*etiology
Esophageal Neoplasms/drug therapy ; Esophageal Neoplasms/pathology ; Female ; Humans ; Male ; Middle Aged ; Quality of Life ; Sarcopenia/pathology
References:
Radiat Oncol. 2015 Jan 13;10:16. (PMID: 25582305)
Br J Anaesth. 2016 Feb;116(2):177-91. (PMID: 26787788)
Biol Res Nurs. 2008 Jul;10(1):7-20. (PMID: 18705151)
J Am Med Dir Assoc. 2011 Jul;12(6):403-9. (PMID: 21640657)
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778-788. (PMID: 28614627)
World J Gastroenterol. 2011 Nov 14;17(42):4660-74. (PMID: 22180708)
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. (PMID: 12091180)
Eur J Surg Oncol. 2017 Feb;43(2):478-484. (PMID: 28024944)
J Geriatr Oncol. 2014 Jan;5(1):49-56. (PMID: 24484718)
World J Surg. 2014 Sep;38(9):2345-51. (PMID: 24756548)
Eur J Surg Oncol. 2014 Oct;40(10):1313-20. (PMID: 24731268)
J Nutr Health Aging. 2016 Jan;20(1):3-7. (PMID: 26728926)
Age Ageing. 2010 Jul;39(4):412-23. (PMID: 20392703)
Pract Radiat Oncol. 2016 May-Jun;6(3):e53-9. (PMID: 26725962)
Qual Life Res. 1998 Jan;7(1):75-83. (PMID: 9481153)
J Cardiothorac Surg. 2011 Aug 15;6:98. (PMID: 21843340)
Clin Oncol (R Coll Radiol). 2005 Dec;17(8):639-45. (PMID: 16372491)
BMJ Open. 2014 Mar 27;4(3):e004503. (PMID: 24674997)
Nutr Res. 2013 Mar;33(3):171-9. (PMID: 23507222)
J Surg Oncol. 2016 May;113(6):678-84. (PMID: 26936808)
Eur J Cancer Prev. 1997 Apr;6(2):118-24. (PMID: 9237058)
J Clin Anesth. 2016 Dec;35:446-455. (PMID: 27871573)
J Clin Oncol. 2007 Oct 1;25(28):4396-404. (PMID: 17785708)
Lancet Oncol. 2008 Jul;9(7):629-35. (PMID: 18539529)
Support Care Cancer. 2014 Nov;22(11):3035-44. (PMID: 24908429)
Am J Clin Oncol. 2013 Feb;36(1):53-6. (PMID: 22157214)
Eur J Surg Oncol. 2015 Mar;41(3):333-8. (PMID: 25498359)
Ann Surg. 2017 Nov;266(5):822-830. (PMID: 28796017)
Clin Nutr. 2012 Feb;31(1):74-7. (PMID: 21875767)
N Engl J Med. 2012 May 31;366(22):2074-84. (PMID: 22646630)
Dis Esophagus. 2017 Jan 1;30(1):1-12. (PMID: 27862675)
J Gerontol A Biol Sci Med Sci. 2005 Nov;60(11):1425-31. (PMID: 16339329)
BMC Cancer. 2017 Jun 3;17 (1):401. (PMID: 28578652)
Dig Dis Sci. 1988 Feb;33(2):129-34. (PMID: 3123181)
Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. (PMID: 20559064)
N Engl J Med. 2006 Jul 6;355(1):11-20. (PMID: 16822992)
Clin Nutr. 2017 Feb;36(1):11-48. (PMID: 27637832)
Clin Nutr. 2005 Feb;24(1):75-82. (PMID: 15681104)
Grant Information:
HPA-POR-2014-535 Ireland Health Research Board
Contributed Indexing:
Keywords: Neoadjuvant therapy; Oesophageal cancer; Physical fitness; Sarcopenia
Entry Date(s):
Date Created: 20171204 Date Completed: 20190130 Latest Revision: 20220409
Update Code:
20240104
DOI:
10.1007/s00520-017-3993-0
PMID:
29197960
Czasopismo naukowe
Purpose: Preoperative chemo(radio)therapy for oesophageal cancer (OC) may have an attritional impact on body composition and functional status, impacting postoperative outcome. Physical decline with skeletal muscle loss has not been previously characterised in OC and may be amenable to physical rehabilitation. This study characterises skeletal muscle mass and physical performance from diagnosis to post-neoadjuvant therapy in patients undergoing preoperative chemo(radio)therapy for OC.
Methods: Measures of body composition (axial computerised tomography), muscle strength (handgrip), functional capacity (walking distance), anthropometry (weight, height and waist circumference), physical activity, quality-of-life and nutritional status were captured prospectively. Sarcopenia status was defined as pre-sarcopenic (low muscle mass only), sarcopenic (low muscle mass and low muscle strength or function) or severely sarcopenic (low muscle mass and low muscle strength and low muscle function).
Results: Twenty-eight participants were studied at both time points (mean age 62.86 ± 8.18 years, n = 23 male). Lean body mass reduced by 4.9 (95% confidence interval 3.2 to 6.7) kg and mean grip strength reduced by 4.3 (2.5 to 6.1) kg from pre- to post-neoadjuvant therapy. Quality-of-life scores capturing gastrointestinal symptoms improved. Measures of anthropometry, walking distance, physical activity and nutritional status did not change. There was an increase in sarcopenic status from diagnosis (pre-sarcopenic n = 2) to post-treatment (pre-sarcopenic n = 5, severely sarcopenic n = 1).
Conclusions: Despite maintenance of body weight, functional capacity and activity habits, participants experience declines in muscle mass and strength. Interventions involving exercise and/or nutritional support to build muscle mass and strength during preoperative therapy, even in patients who are functioning normally, are warranted.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies